SynthesisRheumatology (Oxford, England)2022
Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.
Synthesis in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Corticosteroid Usage in Modeling Gulf War Illness in Pre-Clinical Models: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.Annals of the rheumatic diseases · 2024Guideline
- [Erythroderma: etiology, diagnosis, and management-an overview].Dermatologie (Heidelberg, Germany) · 2026Review
- Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.International journal of molecular sciences · 2026Review
- The Uncommon Coexistence of Mid-Borderline Leprosy and Generalized Pustular Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Article
- Chrysoeriol Alleviates Psoriasis Inflammation and Keratinocyte Hyperproliferation Possibly Through Inhibiting AKT/NF-κB Signaling Activation.Journal of inflammation research · 2026Article
- Bridging with a single glucocorticoid injection in psoriatic arthritis: Real-world evidence of short-term effectiveness, safety, and enhanced response in high-inflammatory burden patients.Therapeutic advances in musculoskeletal disease · 2026Article
- Myricetin Attenuates IMQ-Induced Psoriatic Inflammation Through Multi-Target Modulation: Evidence from Network Pharmacology and Experimental Validation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden.Lupus science & medicine · 2025Article
- Article
- Article
- Data mining historical Chinese medical recipe collections and nuclear receptor profiling identify plant fractions that modulate glucocorticoid receptor activity.Frontiers in pharmacology · 2025Article
- Topical Glucocorticoid-Induced Cushing's Syndrome in a Patient with Erythrodermic Psoriasis: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Article
- Cardiovascular comorbidities in psoriatic arthritis: state of the art.Therapeutic advances in musculoskeletal disease · 2024Review
- Diagnostic Value of Short Course Low-dose Prednisolone in Patients with Clinically Suspected Seronegative Inflammatory Arthritis - A Retrospective Study.Current rheumatology reviews · 2024Article
- Infections in psoriatic arthritis: association with treatment.Therapeutic advances in musculoskeletal disease · 2024Review
- Review
- Drug-related psoriasis.Postepy dermatologii i alergologii · 2023Article
- Case Report: Paraneoplastic psoriasis in thymic carcinoma.Frontiers in oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe use of systemic glucocorticoids (SGCs) is traditionally discouraged in the treatment of PsA and psoriasis due to the risk of psoriatic flares. However, despite this recommendation, SGCs are frequently prescribed for these patients. In this study we reappraise the old paradigm that SGCs are contra-indicated in the treatment of PsA and psoriasis.
methodsA systematic search of MEDLINE, EMBASE and the Cochrane Library databases was performed in November 2019 to identify articles on any SGC use compared with no use in the PsA and psoriasis population. Topical glucocorticoid treatment was excluded. Our two primary outcomes focused on the prescribing characteristics and the occurrence of any type of flare.
resultsOur search yielded 4922 articles, and of these 21 full-text articles were eligible for inclusion. There were 11 retro- and prospective cohorts involving a total of 4,171,307 patients. Of these, 6727 (37.82%) of the patients with PsA and 1 460 793 (35.17%) of the patients with psoriasis were treated with any type of SGC. Ten observational/interventional studies did not report an increased risk or occurrence of psoriatic flares related to SGC use.
conclusionOur results indicate that SGCs are frequently prescribed for PsA and psoriasis patients. The occurrence of psoriatic flares appears to be low upon SGC exposure. In patients with a clear indication for SGCs, e.g. in need of rapid anti-inflammatory therapy or bridging of therapies, the use of SGCs should be considered in view of the low risk of skin flaring. It remains of importance to weigh risks for short- and long-term SGC-related side effects in clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.